Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization

Naoya Fujita1, Saori Sato, Kazuhiro Katayama

  • 1Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo 113-0032, Japan.

Insights

The Akt kinase phosphorylates p27(Kip1) at Thr198, promoting its binding to 14-3-3 proteins. This interaction leads to p27(Kip1) cytoplasmic localization, driving cell-cycle progression in human cancers.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Low p27(Kip1) expression in human cancers correlates with poor survival.
  • Akt signaling inhibition can induce cell-cycle arrest via p27(Kip1) upregulation.
  • The precise role of Akt-dependent phosphorylation in p27(Kip1) regulation remains unclear.

Purpose of the Study:

  • To elucidate the role of Akt-dependent phosphorylation in p27(Kip1) regulation.
  • To identify specific phosphorylation sites on p27(Kip1) targeted by Akt.
  • To investigate the functional consequences of Akt-mediated p27(Kip1) phosphorylation.

Main Methods:

  • Direct binding assays between Akt and p27(Kip1).
  • Phosphorylation site mapping of p27(Kip1) by Akt.
  • Analysis of 14-3-3 protein binding to phosphorylated p27(Kip1).
  • Cellular localization studies of p27(Kip1).

Main Results:

  • Akt directly binds and phosphorylates p27(Kip1).
  • Thr198 is identified as a novel Akt phosphorylation site on p27(Kip1).
  • Akt-mediated phosphorylation of Thr198 facilitates 14-3-3 protein binding.
  • Phosphorylated p27(Kip1) at Thr198 is localized to the cytoplasm, unlike other sites.
  • Akt promotes cell-cycle progression through p27(Kip1) phosphorylation and cytoplasmic retention.

Conclusions:

  • Akt-dependent phosphorylation of p27(Kip1) at Thr198 is a key regulatory mechanism.
  • This phosphorylation event drives 14-3-3 binding and cytoplasmic localization of p27(Kip1).
  • These findings reveal a novel pathway by which Akt promotes cancer cell proliferation.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...